Inmagene is a leading biotech company focused on immunology-related therapeutic areas.
With wholly owned subsidiaries in San Diego, Shanghai and Hangzhou, the company is building a robust pipeline of over
10 drug candidates. IMG-20, Inmagene’s most advanced drug candidate, is about to enter the global registration trials
for multiple indications.
Inmagene has a seasoned management team. In prior experience, the team members played important roles in the founding
of Zai Lab (NASDAQ: ZLAB), I-Mab (NASDAQ: IMAB) and Apollomics, led the drug development for over 20 successful NDAs,
in-licensed over 30 global products for China, obtained market approvals in 28 countries, and pushed 6 drug candidates
from discovery to human trials in both China and the United States.
Inmagene’s pipeline is driven by two "engines". First, Inmagene in-licenses clinical-stage foreign products which fit
China, and, together with its overseas partners, carries out global multi-center clinical trials. Also, Inmagene utilizes
China's cost-efficient resources to create drugs with best-in-class potentials. It has initiated four innovative programs
for validated drug targets.